paritaprevir (BioDeep_00000837618)
代谢物信息卡片
paritaprevir
化学式: C40H43N7O7S (765.2944528)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CN=C(C=N1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8
InChI: InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1
描述信息
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- PubChem: 45110509
- DrugBank: DB09297
- ChEMBL: CHEMBL3391662
- CAS: 1221573-85-8
- CAS: 1216941-48-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Xenia Bacinschi, Gabriel Cristian Popescu, Anca Zgura, Laurentia Gales, Anghel Rodica, Adriana Mercan, Dragos Serban, Bogdan Haineala, Letitia Toma, Laura Iliescu. A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.
Medical science monitor : international medical journal of experimental and clinical research.
2022 Jul; 28(?):e936706. doi:
10.12659/msm.936706. [PMID: 35787600] - Xenia Bacinschi, Adriana Mercan-Stanciu, Letitia Toma, Anca Zgura, Nicolae Bacalbasa, Chen-Peng Ifrim, Camelia Diaconu, Laura Iliescu, Radu Valeriu Toma. Glycemic Control in Patients Undergoing Treatment With Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir for Chronic Hepatitis C Infection.
In vivo (Athens, Greece).
2022 May; 36(3):1438-1443. doi:
10.21873/invivo.12849. [PMID: 35478152] - Yuna Sadaka, Midori Soda, Akiyo Hori, Yuri Miyahara, Yasuhisa Oida, Yoichi Nishigaki, Eiichi Tomita, Takashi Mizui, Kiyoyuki Kitaichi. Combined Use of Calcium-channel Blockers With Ombitasvir/Paritaprevir/Ritonavir Exacerbates Peripheral Edema in Elderly Japanese Patients.
Anticancer research.
2022 04; 42(4):2087-2093. doi:
10.21873/anticanres.15690. [PMID: 35347032] - Fabrizio Fabrizi, Cristina Alonso, Ana Palazzo, Margarita Anders, Maria Virginia Reggiardo, Hugo Cheinquer, Maria Grazia Videla Zuain, Sebastian Figueroa, Manuel Mendizabal, Marcelo Silva, Ezequiel Ridruejo. 'Real-life' experience with direct-acting antiviral agents for HCV after kidney transplant.
Annals of hepatology.
2021 Nov; 25(?):100337. doi:
10.1016/j.aohep.2021.100337. [PMID: 33684523] - Feroza Begum, Amit Kumar Srivastava, Upasana Ray. Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight.
Biochemical and biophysical research communications.
2021 09; 571(?):26-31. doi:
10.1016/j.bbrc.2021.07.050. [PMID: 34303192] - Yudibeth Sixto-López, Marlet Martínez-Archundia. Drug repositioning to target NSP15 protein on SARS-CoV-2 as possible COVID-19 treatment.
Journal of computational chemistry.
2021 05; 42(13):897-907. doi:
10.1002/jcc.26512. [PMID: 33713492] - Bülent Değertekin, Mehmet Demir, Ulus S Akarca, Haluk Tarık Kani, Enver Üçbilek, Emre Yıldırım, Fatih Güzelbulut, Ayhan Balkan, Sezgin Vatansever, Nilay Danış, Melek Demircan, Aliye Soylu, Serkan Yaras, Aysun Kartal, Ayşe Kefeli, Feyza Gündüz, Kendal Yalçın, Elife Erarslan, Murat Aladağ, Murat Harputluoğlu, Ayşegül Özakyol, Tuncer Temel, Mesut Akarsu, Hale Sümer, Mete Akın, Bülent Albayrak, İlker Sen, Hüseyin Alkım, Ahmet Uyanıkoğlu, Kader Irak, Sinem Öztaşkın, Çağrı Burak Uğurlu, Şevkican Güneş, Selim Gürel, Kenan Nuriyev, İsmail İnci, Sabite Kaçar, Dinç Dinçer, Levent Doğanay, Hüseyin Savaş Göktürk, Ali Mert, Arif Mansur Coşar, Hakan Dursun, Roni Atalay, Sabiye Akbulut, Yasemin Balkan, Hayrettin Koklu, Halis Şimşek, Osman Özdoğan, Mehmet Çoban. Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
2020 12; 31(12):883-893. doi:
10.5152/tjg.2020.20696. [PMID: 33626001] - Sherief Abd-Elsalam, Yousry Esam-Eldin Abo-Amer, Mohamed El-Abgeegy, Samah A Elshweikh, Heba Fadl Elsergany, Rehab Ahmed, Mahmoud Elkadeem, Nehad Hawash, Shaimaa Soliman, Rehab Badawi, Ayman Mohammed Abdou Elguindy, Moataz Yousry Soliman, Ahmed Abdelhaleem Mohmed, Loai Mansour. Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience.
Medicine.
2020 Oct; 99(42):e21972. doi:
10.1097/md.0000000000021972. [PMID: 33080669] - Donald D Anthony, Mark S Sulkowski, Laura M Smeaton, Sofi Damjanovska, Carey L Shive, Corinne M Kowal, Daniel E Cohen, Debika Bhattacharya, Beverly L Alston-Smith, Ashwin Balagopal, David L Wyles. Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
The Journal of infectious diseases.
2020 09; 222(8):1334-1344. doi:
10.1093/infdis/jiaa254. [PMID: 32406487] - Ashwin Balagopal, Laura M Smeaton, Jeffrey Quinn, Charles S Venuto, Gene D Morse, Vincent Vu, Beverly Alston-Smith, Daniel E Cohen, Jorge L Santana-Bagur, Donald D Anthony, Mark S Sulkowski, David L Wyles, Andrew H Talal. Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy.
The Journal of infectious diseases.
2020 07; 222(4):601-610. doi:
10.1093/infdis/jiaa126. [PMID: 32201883] - Osman Özdoğan, Serkan Yaraş, Fehmi Ateş, Enver Üçbilek, Orhan Sezgin, Engin Altıntaş. The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
2020 05; 31(5):384-392. doi:
10.5152/tjg.2020.19273. [PMID: 32519958] - Faten Farouk, Dina Wahba, Sherif Mogawer, Shaimaa Elkholy, Ahmed Elmeligui, Reham Abdelghani, Salwa Ibahim. Development and Validation of a New LC-MS/MS Analytical Method for Direct-Acting Antivirals and Its Application in End-Stage Renal Disease Patients.
European journal of drug metabolism and pharmacokinetics.
2020 Feb; 45(1):89-99. doi:
10.1007/s13318-019-00584-6. [PMID: 31667795] - Elena Laura Iliescu, Adriana Mercan-Stanciu, Letitia Toma. Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease.
BMC nephrology.
2020 01; 21(1):21. doi:
10.1186/s12882-020-1687-1. [PMID: 31948406] - Charles S Venuto, Yoninah S Cramer, Susan L Rosenkranz, Mark Sulkowski, David L Wyles, Daniel E Cohen, Jeffrey Schmidt, Beverly L Alston-Smith, Gene D Morse. Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s.
British journal of clinical pharmacology.
2020 01; 86(1):132-142. doi:
10.1111/bcp.14148. [PMID: 31656054] - Ezequiel Ridruejo, Rebeca Garcia-Agudo, Manuel Mendizabal, Sami Aoufi-Rabih, Vivek Dixit, Marcelo Silva, Fabrizio Fabrizi. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
Nefrologia.
2020 Jan; 40(1):46-52. doi:
10.1016/j.nefro.2019.03.013. [PMID: 31229261] - Bengu Tatar, Şükran Köse, Nadide Colak Ergun, Melda Turken, Yusuf Onlen, Yusuf Yılmaz, Sıla Akhan. Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.
Revista da Associacao Medica Brasileira (1992).
2019 Dec; 65(12):1470-1475. doi:
10.1590/1806-9282.65.12.1470. [PMID: 31994628] - Johannes Wiegand, Peter Buggisch, Stefan Mauss, Klaus H W Boeker, Hartwig Klinker, Tobias Müller, Rainer Günther, Yvonne Serfert, Michael P Manns, Stefan Zeuzem, Thomas Berg, Holger Hinrichsen, German Hepatitis C-Registry. Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
European journal of gastroenterology & hepatology.
2019 Nov; 31(11):1424-1431. doi:
10.1097/meg.0000000000001426. [PMID: 31589184] - Nikolina Bukal, Vesna Furic-Cunko, Ivana Juric, Lea Katalinic, Antonia Dedo, Nikolina Basic-Jukic. Severe hepatotoxicity of ritonavir, ombitasvir, paritaprevir, and dasabuvir in a kidney transplant recipient.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.
2019 Sep; 30(5):1184-1186. doi:
10.4103/1319-2442.270279. [PMID: 31696862] - Nilay Danış, Hüseyin Toz, Nalan Ünal, Mümtaz Yılmaz, İlker Turan, Fulya Günşar, Zeki Karasu, Galip Ersöz, Mehmet Özkahya, Ulus Salih Akarca. Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
2019 Aug; 30(8):695-701. doi:
10.5152/tjg.2019.18833. [PMID: 31418413] - Serkan Yaraş, Enver Üçbilek, Osman Özdoğan, Fehmi Ateş, Engin Altıntaş, Orhan Sezgin. Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
2019 Apr; 30(4):331-335. doi:
10.5152/tjg.2018.18269. [PMID: 30666967] - Necati Örmeci, Orhan Sezgin, Ridvan Karaali, Bilgehan Aygen, Dilara Turan, Serkan Yaras, İlknur Erdem, Orhan Yildiz, Fatih Karakaya, Kenan Ateş, Özgün Ö Asiller. Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences.
European journal of gastroenterology & hepatology.
2019 04; 31(4):534-539. doi:
10.1097/meg.0000000000001334. [PMID: 30672829] - Francesc Maduell, Lara Belmar, Jésica Ugalde, Montserrat Laguno, María Martínez-Rebollar, Raquel Ojeda, Marta Arias, Lida Rodas, Florencia Rossi, Laura-Patricia Llovet, Leonardo Nicolás González, Josep Mallolas, Maria-Carlota Londoño. Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
Gastroenterologia y hepatologia.
2019 Mar; 42(3):164-170. doi:
10.1016/j.gastrohep.2018.07.015. [PMID: 30293914] - Diğdem Özer Etik, Nuretdin Suna, Serkan Öcal, Haldun Selçuk, Ülkü Dağlı, Turan Çolak, Fatih Hilmioğlu, Ahmet Sedat Boyacıoğlu, Mehmet Haberal. Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.
2019 02; 17(1):52-58. doi:
10.6002/ect.2018.0095. [PMID: 30719954] - Noriaki Orita, Tetsuro Shimakami, Hajime Sunagozaka, Rika Horii, Kouki Nio, Tekeshi Terashima, Noriho Iida, Masaaki Kitahara, Hajime Takatori, Kazunori Kawaguchi, Kazuya Kitamura, Kuniaki Arai, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko. Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation.
Clinical journal of gastroenterology.
2019 Feb; 12(1):63-70. doi:
10.1007/s12328-018-0884-y. [PMID: 29995231] - Jiuhong Zha, Bifeng Ding, Haoyu Wang, Weihan Zhao, Chen Yu, Katia Alves, Niloufar Mobashery, Yan Luo, Rajeev M Menon. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
European journal of drug metabolism and pharmacokinetics.
2019 Feb; 44(1):43-52. doi:
10.1007/s13318-018-0492-8. [PMID: 29909549] - Mohamed A Mekky, Mohamed O Abdel-Malek, Heba A Osman, Essam M Abdel-Aziz, Abdel-Kader A Hashim, Helal F Hetta, Khairy H Morsy. Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease.
Clinics and research in hepatology and gastroenterology.
2019 02; 43(1):82-87. doi:
10.1016/j.clinre.2018.08.003. [PMID: 30166253] - Haruki Uojima, Shuzo Kobayashi, Hisashi Hidaka, Takeshi Kinbara, Tomoaki Fujikawa, Tsuyoshi Nakayama, Hiroki Yamanoue, Takayuki Kanemaru, Tohru Hashimotoh, Ji Hyun Sung, Makoto Kako, Wasaburo Koizumi. Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients.
Annals of hepatology.
2019 Jan; 18(1):109-115. doi:
10.5604/01.3001.0012.7868. [PMID: 31113578] - María-Carlota Londoño, Mar Riveiro-Barciela, Adriana Ahumada, Raquel Muñoz-Gómez, Mercé Roget, María J Devesa-Medina, Miguel Ángel Serra, Carmen A Navascués, Carme Baliellas, Teresa Aldamiz-Echevarría, María L Gutiérrez, Benjamín Polo-Lorduy, Isabel Carmona, Salvador Benlloch, Lucía Bonet, Javier García-Samaniego, Miguel Jiménez-Pérez, Senador Morán-Sánchez, Ángeles Castro, Manuel Delgado, Francisco Gea-Rodríguez, Ignacio Martín-Granizo, María Luisa Montes, Luís Morano, Manuel A Castaño, Ignacio de Los Santos, Montserrat Laguno, Juan Emilio Losa, Marta Montero-Alonso, Antonio Rivero, Cristina de Álvaro, Amanda Manzanares, Josep Mallolas, Guillermina Barril, Emilio González-Parra, Luisa García-Buey. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
PloS one.
2019; 14(9):e0221567. doi:
10.1371/journal.pone.0221567. [PMID: 31550267] - Mohamed Said, Heba Omar, Zeinab Soliman, Yasmin Saad, Hosam Dabes, Sozan Hamed, Kadri ElSaeed, Yehia ElShazly, Magdi ElSerafy. Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
Expert review of gastroenterology & hepatology.
2019 Jan; 13(1):89-93. doi:
10.1080/17474124.2019.1544070. [PMID: 30791838] - Faisal M Sanai, Abdullah S Alghamdi, Ahmad A Afghani, Khalid Alswat, Adnan AlZanbagi, Mosfer N Alghamdi, Abdallah AlMousa, Mohammed Aseeri, Abdullah M Assiri, Mohamed A Babatin. High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Liver international : official journal of the International Association for the Study of the Liver.
2018 08; 38(8):1395-1401. doi:
10.1111/liv.13674. [PMID: 29288514] - W Abdel-Razek, I Waked. Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?.
Alimentary pharmacology & therapeutics.
2018 08; 48(3):379-380. doi:
10.1111/apt.14831. [PMID: 29998505] - A A Butt, Y Ren, A Puenpatom, J M Arduino, R Kumar, A-B Abou-Samra. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
Alimentary pharmacology & therapeutics.
2018 07; 48(1):35-43. doi:
10.1111/apt.14799. [PMID: 29797514] - Takeshi Hirayama, Tadashi Ikegami, Akira Honda, Teruo Miyazaki, Sho-Ichiro Yara, Motoyuki Kohjima, Makoto Nakamuta, Yasushi Matsuzaki. Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Internal medicine (Tokyo, Japan).
2018 May; 57(9):1219-1227. doi:
10.2169/internalmedicine.9479-17. [PMID: 29279486] - S Takeuchi, M Takamura, T Yoshida, K Takahashi, K Hayashi, S Hashimoto, S Yamagiwa, M Tasaki, Y Nakagawa, K Saito, Y Tanabe, Y Tomita, S Terai. Ombitasvir-Paritaprevir-Ritonavir Therapy in a Kidney Transplant Recipient With Chronic Hepatitis C Virus Genotype 1 Infection: A Case Report on the Importance of Considering Drug-Drug Interactions and Monitoring Cyclosporine Levels.
Transplantation proceedings.
2018 Apr; 50(3):884-886. doi:
10.1016/j.transproceed.2018.01.006. [PMID: 29661458] - Yukihiro Yoshimura, Nobuyuki Miyata, Hirokazu Komatsu, Natsuo Tachikawa. Remarkable plasma HIV RNA decrease by ombitasvir/paritaprevir/ritonavir in an HIV-HCV coinfection case.
AIDS (London, England).
2018 01; 32(1):128-129. doi:
10.1097/qad.0000000000001665. [PMID: 29210779] - Hironao Okubo, Hitoshi Ando, Yushi Sorin, Eisuke Nakadera, Hiroo Fukada, Junichi Morishige, Akihisa Miyazaki, Kenichi Ikejima. Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.
PloS one.
2018; 13(4):e0196747. doi:
10.1371/journal.pone.0196747. [PMID: 29709031] - Fabrizio Fabrizi, Francesco Negro, Mark Bondin, Patrice Cacoub. Expert opinion on the management of renal manifestations of chronic HCV infection.
Antiviral therapy.
2018; 23(Suppl 2):57-67. doi:
10.3851/imp3247. [PMID: 30451153] - Yi-Chung Hsieh, Wen-Juei Jeng, Chien-Hao Huang, Wei Teng, Wei-Ting Chen, Yi-Cheng Chen, Shi-Ming Lin, Dar-In Tai, Chun-Yen Lin, I-Shyan Sheen. Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
PloS one.
2018; 13(8):e0202777. doi:
10.1371/journal.pone.0202777. [PMID: 30138456] - Massimo Tempestilli, Gabriele Fabbri, Ilaria Mastrorosa, Laura Timelli, Stefania Notari, Rita Bellagamba, Raffaella Libertone, Federico Lupi, Mauro Zaccarelli, Andrea Antinori, Chiara Agrati, Adriana Ammassari. Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world.
The Journal of antimicrobial chemotherapy.
2018 Jan; 73(1):160-164. doi:
10.1093/jac/dkx348. [PMID: 29106584] - Jan Sperl, Miluse Kreidlova, Dusan Merta, Klara Chmelova, Renata Senkerikova, Sona Frankova. Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.
Kidney & blood pressure research.
2018; 43(2):594-605. doi:
10.1159/000488965. [PMID: 29669332] - Novera Alam, Mia G Angeli, David J Greenblatt. Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.
The Journal of pharmacy and pharmacology.
2017 Dec; 69(12):1794-1801. doi:
10.1111/jphp.12821. [PMID: 28990653] - Hiromi Kan, Michio Imamura, Yoshiiku Kawakami, Kana Daijo, Yuji Teraoka, Fumi Honda, Yuki Nakamura, Kei Morio, Tomoki Kobayashi, Takashi Nakahara, Yuko Nagaoki, Tomokazu Kawaoka, Masataka Tsuge, Hiroshi Aikata, Clair Nelson Hayes, Daiki Miki, Hidenori Ochi, Yoji Honda, Nami Mori, Shintaro Takaki, Keiji Tsuji, Kazuaki Chayama. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Journal of medical virology.
2017 11; 89(11):1963-1972. doi:
10.1002/jmv.24885. [PMID: 28657143] - Rajeev M Menon, Akshanth R Polepally, Amit Khatri, Walid M Awni, Sandeep Dutta. Clinical Pharmacokinetics of Paritaprevir.
Clinical pharmacokinetics.
2017 10; 56(10):1125-1137. doi:
10.1007/s40262-017-0520-x. [PMID: 28236252] - Jennifer E Stark, Jennifer Cole. Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2017 Oct; 74(19):1541-1544. doi:
10.2146/ajhp160729. [PMID: 28947525] - Adeel Ajwad Butt, Peng Yan, Tracey G Simon, Abdul-Badi Abou-Samra. Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2017 Sep; 65(6):1006-1011. doi:
10.1093/cid/cix364. [PMID: 28903508] - Francesca Romana Ponziani, Massimo Siciliano, Raffaella Lionetti, Caterina Pasquazzi, Laura Gianserra, Gianpiero D'Offizi, Antonio Gasbarrini, Maurizio Pompili. Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2017 Aug; 70(2):297-300. doi:
10.1053/j.ajkd.2017.01.037. [PMID: 28258770] - Jürgen Kurt Rockstroh, Jordan J Feld, Stéphane Chevaliez, Kevin Cheng, Heiner Wedemeyer, Christoph Sarrazin, Benjamin Maasoumy, Christine Herman, John Hackett, Daniel E Cohen, George J Dawson, Gavin Cloherty, Jean-Michel Pawlotsky. HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.
Journal of virological methods.
2017 07; 245(?):14-18. doi:
10.1016/j.jviromet.2017.03.002. [PMID: 28359920] - Mohamad Shebley, Jinrong Liu, Olga Kavetskaia, Jens Sydor, Sonia M de Morais, Volker Fischer, Marjoleen J M A Nijsen, Daniel A J Bow. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Drug metabolism and disposition: the biological fate of chemicals.
2017 07; 45(7):755-764. doi:
10.1124/dmd.116.074518. [PMID: 28483778] - Charles S Venuto, Marianthi Markatou, Yvonne Woolwine-Cunningham, Rosemary Furlage, Andrew J Ocque, Robin DiFrancesco, Emily O Dumas, Paul K Wallace, Gene D Morse, Andrew H Talal. Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques.
Antimicrobial agents and chemotherapy.
2017 05; 61(5):. doi:
10.1128/aac.02283-16. [PMID: 28264852] - Akshanth R Polepally, Prajakta S Badri, Doerthe Eckert, Sven Mensing, Rajeev M Menon. Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
European journal of drug metabolism and pharmacokinetics.
2017 Apr; 42(2):333-339. doi:
10.1007/s13318-016-0341-6. [PMID: 27165046] - Sven Mensing, Doerthe Eckert, Shringi Sharma, Akshanth R Polepally, Amit Khatri, Thomas J Podsadecki, Walid M Awni, Rajeev M Menon, Sandeep Dutta. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
British journal of clinical pharmacology.
2017 03; 83(3):527-539. doi:
10.1111/bcp.13138. [PMID: 27662429] - David Wyles, Michael Saag, Rolando M Viani, Jacob Lalezari, Oluwatoyin Adeyemi, Laveeza Bhatti, Amit Khatri, Jennifer R King, Yiran B Hu, Roger Trinh, Nancy S Shulman, Peter Ruane. TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
The Journal of infectious diseases.
2017 02; 215(4):599-605. doi:
10.1093/infdis/jiw597. [PMID: 28329334] - Amit Khatri, Sandeep Dutta, Thomas C Marbury, Richard A Preston, Lino Rodrigues, Haoyu Wang, Walid M Awni, Rajeev M Menon. Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.
Clinical pharmacokinetics.
2017 02; 56(2):153-163. doi:
10.1007/s40262-016-0429-9. [PMID: 27389403] - Jennifer R King, Amit Khatri, Roger Trinh, Rolando M Viani, Bifeng Ding, Jiuhong Zha, Rajeev Menon. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
Antimicrobial agents and chemotherapy.
2017 02; 61(2):. doi:
10.1128/aac.02135-16. [PMID: 27919899] - Marco Masetti, Donatella Magalotti, Elena Martino, Pietro Andreone, Alessandra Scuteri, Marco Zoli. A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis.
Journal of gastrointestinal and liver diseases : JGLD.
2016 Dec; 25(4):559-561. doi:
15403/jgld.2014.1121.254.tti. [PMID: 27981315] - Chung-Feng Huang, Tyng-Yuan Jang, Po-Liang Lu, Ming-Lung Yu. Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report.
Medicine.
2016 Nov; 95(47):e5304. doi:
10.1097/md.0000000000005304. [PMID: 27893666] - M A Gentil, C González-Corvillo, M Perelló, S Zarraga, C Jiménez-Martín, L R Lauzurica, A Alonso, A Franco, D Hernández-Marrero, A Sánchez-Fructuoso. Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
Transplantation proceedings.
2016 Nov; 48(9):2944-2946. doi:
10.1016/j.transproceed.2016.07.034. [PMID: 27932113] - Amit Khatri, Roger Trinh, Weihan Zhao, Thomas Podsadecki, Rajeev Menon. Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Antimicrobial agents and chemotherapy.
2016 10; 60(10):6244-51. doi:
10.1128/aac.00795-16. [PMID: 27503645] - George Marshall. Falling up stairs.
Australian family physician.
2016 Sep; 45(9):658-9. doi:
NULL. [PMID: 27606369] - Akshanth R Polepally, Sven Mensing, Amit Khatri, Denise Beck, Wei Liu, Walid M Awni, Rajeev M Menon, Sandeep Dutta. Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
Clinical pharmacokinetics.
2016 09; 55(9):1091-101. doi:
10.1007/s40262-016-0385-4. [PMID: 27000758] - Imam Waked, Gamal Shiha, Roula B Qaqish, Gamal Esmat, Ayman Yosry, Mohamed Hassany, Reham Soliman, Mohammad A Mohey, Naglaa Allam, Naglaa Zayed, Tarik Asselah, Coleen Hall, Rebecca Redman, Niloufar Mobashery, Wahid Doss. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
The lancet. Gastroenterology & hepatology.
2016 09; 1(1):36-44. doi:
10.1016/s2468-1253(16)30002-4. [PMID: 28404110] - Jianwei Shen, Michael Serby, Aimee Reed, Anthony J Lee, Xiaomei Zhang, Kennan Marsh, Amit Khatri, Rajeev Menon, Olga Kavetskaia, Volker Fischer. Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.
Drug metabolism and disposition: the biological fate of chemicals.
2016 08; 44(8):1164-73. doi:
10.1124/dmd.115.067488. [PMID: 27179127] - Akshanth R Polepally, Jennifer R King, Bifeng Ding, Diana L Shuster, Emily O Dumas, Amit Khatri, Yi-Lin Chiu, Thomas J Podsadecki, Rajeev M Menon. Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
Clinical pharmacokinetics.
2016 08; 55(8):1003-14. doi:
10.1007/s40262-016-0373-8. [PMID: 26895022] - Jerika T Lam, Laura Salazar. New combination antiviral for the treatment of hepatitis C.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2016 Jul; 73(14):1042-50. doi:
10.2146/ajhp150163. [PMID: 27217519] - Dario Cattaneo, Agostino Riva, Emilio Clementi, Laura Milazzo, Cristina Gervasoni. Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
Therapeutic drug monitoring.
2016 06; 38(3):285-7. doi:
10.1097/ftd.0000000000000293. [PMID: 26919548] - Paul J Pockros, K Rajender Reddy, Parvez S Mantry, Eric Cohen, Michael Bennett, Mark S Sulkowski, David E Bernstein, Daniel E Cohen, Nancy S Shulman, Deli Wang, Amit Khatri, Manal Abunimeh, Thomas Podsadecki, Eric Lawitz. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
Gastroenterology.
2016 Jun; 150(7):1590-1598. doi:
10.1053/j.gastro.2016.02.078. [PMID: 26976799] - R M Menon, C E Klein, T J Podsadecki, Y-L Chiu, S Dutta, W M Awni. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.
British journal of clinical pharmacology.
2016 May; 81(5):929-40. doi:
10.1111/bcp.12873. [PMID: 26710243] - J F Waring, E O Dumas, S Abel, E Coakley, D E Cohen, J Wade Davis, T Podsadecki, S Dutta. Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects.
Journal of viral hepatitis.
2016 Feb; 23(2):96-104. doi:
10.1111/jvh.12470. [PMID: 26436610] - Prajakta S Badri, Sandeep Dutta, Haoyu Wang, Thomas J Podsadecki, Akshanth R Polepally, Amit Khatri, Jiuhong Zha, Yi-Lin Chiu, Walid M Awni, Rajeev M Menon. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.
Antimicrobial agents and chemotherapy.
2016 01; 60(1):105-14. doi:
10.1128/aac.01778-15. [PMID: 26459906] - Jiuhong Zha, Prajakta S Badri, Bifeng Ding, Naotaka Uchiyama, Katia Alves, Lino Rodrigues, Rebecca Redman, Sandeep Dutta, Rajeev M Menon. Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects.
Clinical therapeutics.
2015 11; 37(11):2560-71. doi:
10.1016/j.clinthera.2015.09.015. [PMID: 26505529] - Amit Khatri, Rajeev M Menon, Thomas C Marbury, Eric J Lawitz, Thomas J Podsadecki, Victoria M Mullally, Bifeng Ding, Walid M Awni, Barry M Bernstein, Sandeep Dutta. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Journal of hepatology.
2015 Oct; 63(4):805-12. doi:
10.1016/j.jhep.2015.05.029. [PMID: 26070406] - Massimo Colombo. Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
2015 Sep; 47(9):727-33. doi:
10.1016/j.dld.2015.04.003. [PMID: 25937625] - Rajeev M Menon, Prajakta S Badri, Tianli Wang, Akshanth R Polepally, Jiuhong Zha, Amit Khatri, Haoyu Wang, Beibei Hu, Eoin P Coakley, Thomas J Podsadecki, Walid M Awni, Sandeep Dutta. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Journal of hepatology.
2015 Jul; 63(1):20-9. doi:
10.1016/j.jhep.2015.01.026. [PMID: 25646891] - Christophe Hézode, Tarik Asselah, K Rajender Reddy, Tarek Hassanein, Marina Berenguer, Katarzyna Fleischer-Stepniewska, Patrick Marcellin, Coleen Hall, Gretja Schnell, Tami Pilot-Matias, Niloufar Mobashery, Rebecca Redman, Regis A Vilchez, Stanislas Pol. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Lancet (London, England).
2015 Jun; 385(9986):2502-9. doi:
10.1016/s0140-6736(15)60159-3. [PMID: 25837829] - Ashley Arezou Minaei, Kris V Kowdley. ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus.
Expert opinion on pharmacotherapy.
2015 Apr; 16(6):929-37. doi:
10.1517/14656566.2015.1024653. [PMID: 25800085] - Mark S Sulkowski, Joseph J Eron, David Wyles, Roger Trinh, Jay Lalezari, Chia Wang, Jihad Slim, Laveeza Bhatti, Joseph Gathe, Peter J Ruane, Richard Elion, Fritz Bredeek, Robert Brennan, Gary Blick, Amit Khatri, Krystal Gibbons, Yiran B Hu, Linda Fredrick, Gretja Schnell, Tami Pilot-Matias, Rakesh Tripathi, Barbara Da Silva-Tillmann, Barbara McGovern, Andrew L Campbell, Thomas Podsadecki. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
JAMA.
2015 Mar; 313(12):1223-31. doi:
10.1001/jama.2015.1328. [PMID: 25706092] - T Jake Liang, Marc G Ghany. Therapy of hepatitis C--back to the future.
The New England journal of medicine.
2014 May; 370(21):2043-7. doi:
10.1056/nejme1403619. [PMID: 24795199] - Ivan Gentile, Federico Borgia, Antonio Riccardo Buonomo, Emanuela Zappulo, Giuseppe Castaldo, Guglielmo Borgia. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.
Current medicinal chemistry.
2014; 21(28):3261-70. doi:
10.2174/0929867321666140706125950. [PMID: 25005190]